Abstract:HomeCirculationVol. 137, No. 17Letter by Jin-shan and Xue-bin Regarding Article, “Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Jin-shan and Xue-bin Regarding Article, “Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus” He Jin-shan, MD and Li Xue-bin, MD He Jin-shanHe Jin-shan Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, China. Search for more papers by this author and Li Xue-binLi Xue-bin Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Peking University People’s Hospital, Beijing, China. Search for more papers by this author Originally published24 Apr 2018https://doi.org/10.1161/CIRCULATIONAHA.117.032074Circulation. 2018;137:1874To the Editor:We read with great interest the article presented by Hu and colleagues1 about P2Y12 receptor express in patients with diabetes mellitus, which indicates that platelet P2Y12 receptor expression is significantly increased and the receptor is constitutively activated in patients with type 2 diabetes mellitus. This contributes to platelet hyperactivity and limits antiplatelet drug efficacy in type 2 diabetes mellitus. We have 3 questions about this study. First, the study finds a pathway involving high glucose-reactive oxygen species-nuclear factor-κB increases platelet P2Y12 receptor expression in diabetes mellitus. Is the condition constant or dynamic? Is it related to the level of glucose? Will the platelet P2Y12 receptor expression decrease with better glucose control? Second, do hypoglycemic drugs have effects on the expression of platelet P2Y12 receptor? Do all the hypoglycemic drugs have the same effect? Will we find a combination of antiplatelet and hypoglycemic drugs that can inhibit the platelet P2Y12 receptor best? Last, this study finds that the P2Y12 receptor inverse agonist AR-C78511 is more effective in inhibiting platelet activation and thrombosis compared with cangrelor in platelets of patients with diabetes mellitus. When can we use it in clinical practice? What about adverse effects? Will it increase the risk of bleeding more so than other drugs with strong platelet inhibition effect? We are hoping that more research will help us understand the special cardiovascular risk in diabetes mellitus patients and manage them better.DisclosuresNone.Footnoteshttp://circ.ahajournals.orgReferences1. Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, Ding Z. Platelets express activated P2Y12 receptor in patients with diabetes mellitus.Circulation. 2017; 136:817–833. doi: 10.1161/CIRCULATIONAHA.116.026995.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails April 24, 2018Vol 137, Issue 17 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.032074PMID: 29685938 Originally publishedApril 24, 2018 PDF download Advertisement

Puerarin Inhibits High Glucose-Induced Injury Through Upregulation of HO-1 Expression in Blood Vessels

Protective Effect of Curcumin Against High Glucose-Induced Endoplasmic Reticulum Stress by Downregulation of Cox-2 Expression in Huvecs

Puerarin Protects High Glucose-Induced Injury of Vascular Relaxation by Activation of Heme Oxygenase-1

Effect and mechanism of puerarin on high glucose-induced hypo-responses in vascular contraction

Puerarin protects human umbilical vein endothelial cells against high glucose-induced apoptosis by upregulating heme oxygenase-1 and inhibiting calpain activation.

[High Glucose and Tea Polyphenols on Expression of Matrix Metalloproteinase-2 and Extracellular Matrix Metalloproteinase Inducer in Human Umbilical Vein Endothelial Cells].

Puerarin protects against high glucose-induced acute vascular dysfunction: Role of heme oxygenase-1 in rat thoracic aorta

Essential Oil from Fructus Alpiniae Zerumbet Protects Human Umbilical Vein Endothelial Cells in Vitro from Injury Induced by High Glucose Levels by Suppressing Nuclear Transcription Factor-Kappa B Signaling

Effects of High Glucose on the Activity of GSH-PX,the Expressions of NOS and ICAM-1 in Human Umbilical Vein Endothelial Cells

Protective Effect Of Curcumin Against High Glucose-Induced Endoplasmic Reticulum Stress By Downregulation Of Cox-2 Expression In Human Umbilical Vein Endothelial Cells

Puerarin Inhibits Hyperglycemia-Induced Inter-Endothelial Junction Through Suppressing Endothelial Nlrp3 Inflammasome Activation Via ROS-dependent Oxidative Pathway.

Puerarin suppresses high glucose-induced MCP-1 expression via modulating histone methylation in cultured endothelial cells.

Puerarin ameliorates high glucose-induced MIN6 cell injury by activating PINK1/Parkin-mediated mitochondrial autophagy

High-glucose treatment regulates biological functions of human umbilical vein endothelial cells via Sirt1/FOXO3 pathway

Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling.

Puerarin Repressed High Glucose Mediated Proliferation, Apoptosis And Inflammation Of Hfob 1.19 Cell Through Promoting Expression Of Sirt1

Puerarin May Protect Against Schwann Cell Damage Induced by Glucose Fluctuation

[Gly14]-Humanin Ameliorates High Glucose-Induced Apoptosis by Inhibiting the Expression of MicroRNA-155 in Endothelial Microparticles

Letter by Jin-shan and Xue-bin Regarding Article, “platelets Express Activated P2Y 12 Receptor in Patients with Diabetes Mellitus”

Puerarin Improves Cardiac Function Through Regulation Of Energy Metabolism In Streptozotocin-Nicotinamide Induced Diabetic Mice After Myocardial Infarction

Hydrogen Sulfide Protects Against High Glucose-Induced Human Umbilical Vein Endothelial Cell Injury Through Activating PI3K/Akt/eNOS Pathway